Purpose
|
Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA).
|
Characteristics
|
Source of Compound: synthetic Target: TXA2 antagonist,PDE inhibitor Receptor: PDE,TXA2R
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
97?%
|
Formula
|
C10H7F3O4
|
Solubility
|
DMSO 50 mg/mL, Water <1 mg="" ml="" <="" td="">
1> |